Not an actual patient.
Ready to fight? We’re with you. ONTRUZANT is a prescription medicine approved for the treatment of HER2+ breast cancer. It can be used in combination with certain chemotherapy drugs or alone after treatment with chemotherapy. Patients are selected for therapy based on an FDA-approved test for trastuzumab. We hope you find this information helpful on your patient journey. Let’s get started.
ONTRUZANT treatment can result in heart problems. Serious and sometimes fatal events have occurred. Some patients have had serious and fatal infusion reactions and lung problems. Symptoms usually occur during or within 24 hours of administration. ONTRUZANT can cause harm to an unborn baby, in some cases death of the unborn baby, when taken by a pregnant woman. ONTRUZANT treatment may lead to a worsening of low white blood cell count.